Gashaw Hassen, Abhishek Singh, Gizeshwork Belete, Nidhi Jain, Ivonne De la Hoz, Genesis P Camacho-Leon, Nitsuh K Dargie, Keila G Carrera, Tadesse Alemu, Sharan Jhaveri, Nebiyou Solomon
Nonalcoholic fatty liver disease (NAFLD), also named metabolic dysfunction-associated fatty liver disease (MAFLD), is a progressive disease spectrum encompassing simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, and cirrhosis. It is a clinically silent disease leading to multiple extra-hepatic complications/comorbidities. It is an independent risk factor for cardiovascular disease (CVD), increasing susceptibility to hypertension, atherosclerosis, arrhythmia, myocardial dysfunction, cardiac valve deformation, and venous thrombosis through putative mechanisms including systemic inflammation, endothelial dysfunction, oxidative stress, insulin resistance, and altered lipid metabolism...
May 2022: Curēus